- Home
- ASO vs CDTX Comparison
ASO vs CDTX Comparison
Compare ASO & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASO
- CDTX
- Stock Information
- Founded
- ASO 1938
- CDTX 2012
- Country
- ASO United States
- CDTX United States
- Employees
- ASO N/A
- CDTX N/A
- Industry
- ASO Recreational Games/Products/Toys
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASO Consumer Discretionary
- CDTX Health Care
- Exchange
- ASO Nasdaq
- CDTX Nasdaq
- Market Cap
- ASO 3.0B
- CDTX 2.8B
- IPO Year
- ASO 2020
- CDTX 2015
- Fundamental
- Price
- ASO $42.52
- CDTX $218.69
- Analyst Decision
- ASO Buy
- CDTX Strong Buy
- Analyst Count
- ASO 17
- CDTX 13
- Target Price
- ASO $57.65
- CDTX $124.20
- AVG Volume (30 Days)
- ASO 1.6M
- CDTX 2.0M
- Earning Date
- ASO 12-09-2025
- CDTX 11-06-2025
- Dividend Yield
- ASO 1.22%
- CDTX N/A
- EPS Growth
- ASO N/A
- CDTX N/A
- EPS
- ASO 5.32
- CDTX N/A
- Revenue
- ASO $5,971,497,000.00
- CDTX N/A
- Revenue This Year
- ASO $4.02
- CDTX N/A
- Revenue Next Year
- ASO $6.32
- CDTX N/A
- P/E Ratio
- ASO $8.00
- CDTX N/A
- Revenue Growth
- ASO N/A
- CDTX N/A
- 52 Week Low
- ASO $33.34
- CDTX $14.33
- 52 Week High
- ASO $61.25
- CDTX $218.85
- Technical
- Relative Strength Index (RSI)
- ASO 31.62
- CDTX 89.23
- Support Level
- ASO $43.95
- CDTX $102.46
- Resistance Level
- ASO $44.99
- CDTX $218.85
- Average True Range (ATR)
- ASO 1.63
- CDTX 5.30
- MACD
- ASO -0.34
- CDTX 12.78
- Stochastic Oscillator
- ASO 15.66
- CDTX 99.72
About ASO Academy Sports and Outdoors Inc.
Academy Sports and Outdoors Inc is engaged in the full-line sporting goods and outdoor recreation retailer in the United States. The company's product categories are outdoors, apparel, sports & recreation, and footwear.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.